Levodopa in combination with a peripheral dopadecarboxylase inhibitor (carbidopa or benserazide) is the mainstay of therapy in Parkinson's disease. It significantly improves patient disability' and increases life span to near normal duration.2 However, after 5 years of therapy complications emerge in approximately one half of patients3 and after 10 years these complications are experienced in greater than 80%.'
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The adverse effects include loss of efficacy, psychiatric side effects, and motor fluctuations. The most commonly recognised fluc'tuations' include end of dose failure, peak dose dyskinesia, random on-off phenomenon, and ineffectiveness of individual doses. The mechanisms behind these fluctuations have not been fully elucidated, however, pharmacokinetic and pharmacodynamic factors, and the natural progression of disease appears to be involved.5 Pharmacokinetic factors, reflecting alterations in bioavailability of levodopa in the striatum, seem to be more important when planning therapeutic strategies for end of dose failure, peak dose dyskinesia, and ineffectiveness of individual doses. Although it is suggested that on-off phenomenon is primary related to pharmacodynamic factors (alteration in dopamine receptor number and sensitivity) even this fluctuation tends to occur during a drop in plasma levodopa levels.5 Many therapeutic strategies have been recommended in patients with motor fluctuations to maintain constant levodopa plasma levels and to improve its bioavailability. Most well known of these is to administer frequent, small doses of levodopa/carbidopa. Patients, however, find this plan inconvenient and of limited usefulness. In addition, this strategy may play a role in the formation of more unpredictable responses which occur as a result of longer duration therapy. 6 
Results
Eight patients withdrew from the study within the first 5 weeks (after one week or less oftherapy with Sinemet CR4). Three because ofpsychiatric illness and therapy (one was hospitalised for depression and the other two required antidepressant therapy which excluded them from the study). Two other patients withdrew because ofa worsening ofParkinson's disease with initiation of CR4. In these patients CR4 was either slow to take effect or had no effect at all. They were unwilling to attempt further therapy with higher doses of CR4 before dropping out. One patient had an allergic reaction to the standard Sinemet 25/100 which was apparently related to the yellow dye in the tablet. This had occurred with previous therapy and the reaction was generalised pruritis. Two others gave no particular reasons.
The mean scores for ADL(on), ADL(off), motor exam, H and Y, and S and E (on and off), the number (table 2) . The only significant change from standard Sinemet therapy to CR4 therapy (other than the increase in on time) was an increase in daily dose of levodopa which was 52% higher with CR4 therapy. Non-significant trends were observed in motor exam score which was lower with CR4 therapy and in hours of dyskinesia per day which was lower with CR4 therapy. Two patients with the most substantial decrease in hours ofdyskinesia per day with CR4 were in this subgroup. None of the patients with on-off phenomenon were in this subgroup. Eleven patients experienced dyskinesia at the end of the standard Sinemet treatment period. Of these, nine had a decrease in the number of hours of dyskinesia per day with CR4, two remained the same. None ofthe patients had more hours of dyskinesia with CR4 than standard Sinemet. Three patients with no hours of dyskinesia at the end of the standard Sinemet treatment period experienced mild dyskinesia in the CR4 period; however, this was eliminated by small manipulations of Sinemet CR4 doses resulting in no dyskinesia by the end of the treatment period. Of the nine patients with a decrease in the number of hours of dyskinesia with CR4 only three decreased by more than 1 hour. One patient decreased from 6 hours to 4, one from 10 to 5 and the other from 9 hours to 0.
Statistical comparison revealed that the decrease in hours of dyskinesia per day in the group of nine patients discussed above was significant (table 3) allowing for their evaluation as a separate subgroup *denotes statistical significance.
Three patients experienced unpredictable on-off effect prior to enrolment into this study. None of these patients improved with regard to on time. One patient also had dyskinesia which decreased by I hour per day on Sinemet CR4. Mean age of onset of Parkinson's disease in these three patients was 44-3 (range 35 to 50), mean duration ofdisease was 20 years (range 11 to 26) and mean duration of fluctuations was 5-6 years (range 2 to 10).
Adverse effects experienced while on CR4 were similar to that observed in patients treated with standard Sinemet. Two patients experienced hallucinations, two had light-headedness, one had nausea, and one had slight eosinophila.
Discussion
Other studies evaluating the efficacy of Sinemet CR4 in patients with Parkinson's disease have been reported.' '7 Goetz et al'5 observed that 19 out of20 patients responded to Sinemet CR4. Significant improvement in disability scores, H and Y stage, and hours on per day were observed. Cedarbaum et al'6 and Leibermann et al7 observed that all patients did not respond to CR4 which is in agreement with our findings. Cedarbaum et alr6 observed an increase hours on per day and improvement in the ADL (on) score in 11 of 13 patients; however, no analysis of patient characteristics which might determine response was performed. Cedarbaum et al'6 and Goetz et al5 observed the total daily dose of levodopa to be relatively unchanged in their patients. Despite the fact that this was true for our entire patient population, in the two subgroups of responders which we evaluated the total daily dose was significantly higher in the Sinemet CR4 treatment period. In addition, in the three previous reports of CR4 therapy""'7 fewer doses per day were required with CR4 therapy. We observed that the number of doses per day with CR4 was relatively unchanged as compared with standard Sinemet therapy. Finally, Cedarbaum et al'6 observed an increase in dyskinesia Factor, Sanchez-Ramos, Weiner, Ingenito 86 Efficacy ofSinemet CR4 in subgroups ofpatients with Parkinson's disease in those patients already experiencing that adverse effect. They associated it with higher plasma trough levels of levodopa with CR4 as compared with standard Sinemet and claimed that this level increased with each dose to a point which resulted in increased afternoon dyskinesia. Goetz et al' also observed this increase in trough levels of plasma levodopa and they observed that more patients experienced dyskinesia with CR4; however, the dyskinesia was less severe. Whether or not these trough levels play a role in the occurrence of dyskinesia in patients treated with CR4 remains to be elucidated. In our experience, patients tended to have less dyskinesia despite much higher doses oflevodopa in the CR4 treatment period. As the results ofother double blind and long term evaluations of Sinemet CR4 therapy become available, explanations regarding these differences between studies should emerge.
We compared the efficacy of Sinemet CR4 with standard Sinemet in 22 patients with Parkinson's disease and fluctuations in disability, most notably end of dose failure and dyskinesia. In this group only one parameter ofevaluation was significantly different and that was hours of dyskinesia per day which was lower during CR4 therapy. Severity of disease as measured with the unified Parkinson's disease, H and Y, and S and E scales as well as the number of hours of on time per day was unchanged. Because of the decrease in dyskinesia it is likely that the quality of on time was improved. The daily dosage of levodopa and number of doses per day during CR4 treatment was not significantly different from that observed with standard Sinemet treatment.
We observed that different subgroups of patients responded to CR4 in different ways. Subgroup 1 was characterised by a significant increase in hours on per day. These patients were older at the onset of Parkinson's disease and had a shorter duration ofdisease and fluctuations than the rest of the patients. Subgroup 2 was characterised by the presence of dyskinesia with standard Sinemet therapy and a significant decrease in hours per day of dyskinesia with Sinemet 'CR4. There were no changes in the number of hours on per day. These patients had a younger age of onset of Parkinson's disease and longer duration offluctuations. Both subgroups required a significantly higher daily dose of levodopa with CR4 therapy to attain their respective responses.
Fluctuations in response to levodopa become more complex and less predictable with longer duration of disease and longer duration fluctuations.418 Fluctuations typically begin with end of dose failure. The duration of response becomes variable with time in end of dose failure leading to a less predictable response. With time on-off phenomenon becomes mixed with end of dose failure and in the later stages on-off effect predominates. Young onset Parkinson's disease patients tend to have earlier, more severe fluctuations than older onset patients. '9 We suggest that response to Sinemet CR4 is in part dependent on age of onset of Parkinson's disease, duration of Parkinson's disease, and duration of fluctuations. Those patients with short duration of disease, short duration of fluctuations, and older age of onset of Parkinson's disease, all of which suggest more predictable, less severe fluctuations may tend to respond with an increase in on time per day and less dyskinesia. Those patients with longer duration, more severe fluctuations and dyskinesia and onset of Parkinson's disease at a younger age may respond to Sinemet CR4 with a decrease in dyskinesia without an increase in hours of on time. Those in which unpredictable response to standard Sinemet predominates CR4 may not be effective. A similar pattern of response was observed with intravenous levodopa therapy by Mouradian et al. '8 This variation in response to CR4 depending on duration of disease and fluctations suggests that pharmacodynamic factors may play a more important role in motor fluctuations of long duration. In patients with early stage fluctuations CR4 may be useful by functionally correcting the loss of ability of the nigro-striatal dopaminergic system to buffer variations ofplasma and striatal levodopa. This dysfunction may be due to the natural progression of Parkinson's disease.'820 We conclude that Sinemet CR4 may be useful in subgroups ofpatients characterised by shorter duration and less severe motor fluctuations.
